BEKSAÇ, M. Et Al. 2019. Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey. 17th International Myeloma Workshop .

BEKSAÇ, M., CENGİZ SEVAL, G., PAYDAŞ, S., TUĞLULAR, A. T., ARSLAN, Ö., GÖKER, A. H., ... KAYNAR, L.(2019). Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey . 17th International Myeloma Workshop

BEKSAÇ, MERAL Et Al. "Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey," 17th International Myeloma Workshop, 2019

BEKSAÇ, MERAL Et Al. "Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey." 17th International Myeloma Workshop , 2019

BEKSAÇ, M. Et Al. (2019) . "Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey." 17th International Myeloma Workshop .

@conferencepaper{conferencepaper, author={MERAL BEKSAÇ Et Al. }, title={Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey}, congress name={17th International Myeloma Workshop}, city={}, country={}, year={2019}}